s6y

Rein Therapeutics, Inc.

Ticker
RNTX
CIK
1420565
Industry
Pharmaceutical Preparations
Formerly
Aileron Therapeutics, Inc., AILERON THERAPEUTICS INC

Financials 45

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K/A Annual Report for period ending Dec 31, 2025
  5. 10-K Annual Report for period ending Dec 31, 2025
  6. 10-Q Quarterly Report for period ending Sep 30, 2025
  7. 10-Q Quarterly Report for period ending Jun 30, 2025
  8. 10-Q Quarterly Report for period ending Mar 31, 2025
  9. 10-K/A Annual Report for period ending Dec 31, 2024
  10. 10-K Annual Report for period ending Dec 31, 2024

All 45 financials filings

News 90

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 90 news filings

Ownership 248

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 248 ownership filings

Prospectus 49

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. S-1 General form of registration statement for all companies including face-amount certificate companies
  3. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  4. S-1 General form of registration statement for all companies including face-amount certificate companies
  5. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. S-3 Registration statement for specified transactions by certain issuers
  8. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. 424B5 Prospectus filed pursuant to Rule 424(b)(5)

All 49 prospectus filings

Proxies 25

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  7. DEF 14A Definitive proxy statements
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEF 14A Definitive proxy statements
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 25 proxies filings

Other 70

  1. SCHEDULE 13G
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G/A
  4. SCHEDULE 13G/A
  5. ARS Annual report to security holders
  6. SCHEDULE 13G/A
  7. SCHEDULE 13G
  8. SCHEDULE 13G
  9. SCHEDULE 13G
  10. EFFECT Notice of Effectiveness

All 70 other filings